Lazard Asset Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Lazard Asset Management LLC purchased a new position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 46,463 shares of the biopharmaceutical company’s stock, valued at approximately $47,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of SGMO. Schonfeld Strategic Advisors LLC bought a new position in Sangamo Therapeutics in the 4th quarter valued at $1,744,000. Acuta Capital Partners LLC purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at $755,000. Boothbay Fund Management LLC bought a new position in shares of Sangamo Therapeutics in the fourth quarter worth about $548,000. Cubist Systematic Strategies LLC purchased a new position in Sangamo Therapeutics in the 4th quarter worth about $466,000. Finally, Golden State Equity Partners lifted its holdings in Sangamo Therapeutics by 2,592.3% during the 4th quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company’s stock valued at $332,000 after buying an additional 313,587 shares in the last quarter. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Stock Performance

NASDAQ SGMO opened at $0.47 on Monday. The company has a market cap of $110.36 million, a PE ratio of -0.63 and a beta of 1.46. The firm’s 50 day moving average price is $0.69 and its 200-day moving average price is $1.25. Sangamo Therapeutics, Inc. has a 52-week low of $0.30 and a 52-week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The company had revenue of $6.44 million for the quarter, compared to the consensus estimate of $7.90 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. On average, analysts forecast that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SGMO has been the topic of a number of research analyst reports. Wall Street Zen initiated coverage on shares of Sangamo Therapeutics in a research note on Thursday. They issued a “hold” rating on the stock. Royal Bank of Canada reissued a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Monday, April 7th. Finally, Barclays lowered their target price on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, May 14th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Sangamo Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $4.50.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.